Ⓐ
PeptiBrief
Peptide medicine

PT-141

PT-141 is a regulated peptide medicine with established evidence in defined indications.

Evidence confidence

Human
4/5
Substantial human evidence
3 citations
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
3/5
Reasonable safety characterisation
3 citations

Claimed uses

Mechanisms

Safety notes

Adverse effects, contraindications and monitoring requirements depend on the approved formulation and indication.

Regulation
  • FDA-approved in the United States for acquired, generalized HSDD in premenopausal women; country-specific status must be checked.
  • Prescription or regulated medicine with jurisdiction-specific indications.

References

  1. VYLEESI (bremelanotide injection) prescribing information · 2019
  2. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials · 2019
  3. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder · 2019
Last reviewed
12 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.